8-K: Celularity Acquires Rebound Product to Expand Biomaterials Portfolio

Celularity Inc. has acquired the Rebound allograft matrix product from Sequence LifeScience, Inc. for $5.5 million, aiming to boost its biomaterial sales.

Summary

• Celularity acquired the Rebound product from Sequence LifeScience for a total consideration of $5.5 million.
• The payment includes a $1 million upfront cash payment, up to $4 million in monthly milestone payments based on 20% of net sales, and a $500,000 credit for a previous payment.
• The acquisition closed on October 9, 2024.
• Celularity also entered into an exclusive supply agreement with Sequence for a minimum of six months, while planning to transfer manufacturing internally.
• Celularity's biomaterial sales for the first half of 2024 exceeded $24 million, surpassing the full year 2023 sales.
• The company expects Rebound sales to contribute meaningfully to the fourth quarter of 2024 and help achieve full-year biomaterial sales targets.

Sentiment

Score: 7

Explanation: The document conveys a positive outlook with the acquisition and expected sales growth, but also acknowledges risks, resulting in a moderately positive sentiment.

Positives

• The acquisition of Rebound expands Celularity's portfolio of placental-derived biomaterials.
• The company's biomaterial sales are showing strong growth, with first-half 2024 sales exceeding the full year 2023 sales.
• Rebound is expected to contribute to revenue in the fourth quarter of 2024.
• The acquisition aligns with Celularity's strategic vision of expanding its offerings in regenerative medicine.
• Celularity retains the right to manufacture the Product internally and intends to commence a technology transfer as soon as practicable.

Risks

• The company's liquidity situation could impact its ability to execute its plans.
• There is volatility in Celularity's stock price.
• There are inherent risks in biotechnological development, including the development of novel advanced biomaterials.
• The regulatory approval process could impact the timeline for product commercialization.
• The company's future performance is subject to various risks outlined in its SEC filings.

Future Outlook

Celularity expects Rebound sales to contribute meaningfully in the fourth quarter of 2024 and to fulfill expected full year 2024 biomaterial sales targets. The company also intends to commence a technology transfer to manufacture the product internally.

Management Comments

• Robert J. Hariri, M.D., Ph.D., Chairman, CEO and founder of Celularity, stated that Rebound adds to their portfolio of placental-derived advanced biomaterial products.
• Dr. Hariri also mentioned that the company expects Rebound sales to contribute meaningfully in the fourth quarter 2024 and to fulfill expected full year 2024 biomaterial sales.
• Dr. Hariri expressed pleasure with Celularity's commercial traction and optimism about future performance.

Industry Context

This acquisition reflects a trend in the regenerative medicine industry where companies are expanding their product portfolios through strategic acquisitions to address a broader patient population and enhance their market position. Celularity is leveraging the unique properties of placental tissues to differentiate itself in the market.

Comparison to Industry Standards

• While specific competitor acquisitions are not detailed, the move is consistent with other regenerative medicine companies seeking to expand their product offerings.
• The focus on placental-derived products is a niche area, and Celularity's sales growth in this area is notable compared to companies with more diverse product lines.
• The $5.5 million acquisition cost is relatively modest compared to larger acquisitions in the biotech space, suggesting a targeted approach to growth.

Stakeholder Impact

• Shareholders may view the acquisition positively due to the potential for increased revenue and market share.
• Employees may benefit from the company's growth and expansion.
• Customers may have access to a broader range of advanced biomaterial products.
• Suppliers may see increased demand for placental-derived materials.

Next Steps

• Celularity will integrate the Rebound product into its commercial portfolio.
• The company will commence a technology transfer to manufacture the product internally.
• Celularity will continue to monitor and report on the sales performance of the Rebound product.

Key Dates

Keywords

biomaterials, regenerative medicine, placental-derived, allograft matrix, acquisition, wound care, soft tissue repair, milestone payments, net sales, supply agreement